Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies

In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or weight-lowering effects and a relatively lower risk of hypo...

Descripción completa

Detalles Bibliográficos
Autor principal: Shaefer, Charles F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2016
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833487/
https://www.ncbi.nlm.nih.gov/pubmed/27092017
http://dx.doi.org/10.2337/diaclin.34.2.81
_version_ 1782427367985119232
author Shaefer, Charles F.
author_facet Shaefer, Charles F.
author_sort Shaefer, Charles F.
collection PubMed
description In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or weight-lowering effects and a relatively lower risk of hypoglycemia. This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes.
format Online
Article
Text
id pubmed-4833487
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-48334872017-04-01 Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies Shaefer, Charles F. Clin Diabetes Feature Articles In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or weight-lowering effects and a relatively lower risk of hypoglycemia. This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes. American Diabetes Association 2016-04 /pmc/articles/PMC4833487/ /pubmed/27092017 http://dx.doi.org/10.2337/diaclin.34.2.81 Text en © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.
spellingShingle Feature Articles
Shaefer, Charles F.
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
title Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
title_full Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
title_fullStr Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
title_full_unstemmed Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
title_short Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
title_sort lixisenatide: a new member of the glucagon-like peptide 1 receptor agonist class of incretin therapies
topic Feature Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833487/
https://www.ncbi.nlm.nih.gov/pubmed/27092017
http://dx.doi.org/10.2337/diaclin.34.2.81
work_keys_str_mv AT shaefercharlesf lixisenatideanewmemberoftheglucagonlikepeptide1receptoragonistclassofincretintherapies

Ejemplares similares